Journal
ONCOIMMUNOLOGY
Volume 3, Issue 6, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.29244
Keywords
CTLA-4; MK-3475; PBMC; PD-1; TCR; Tremelimumab; sequencing
Categories
Funding
- NCATS NIH HHS [UL1 TR000124] Funding Source: Medline
- NCI NIH HHS [P30 CA016042] Funding Source: Medline
- NIAID NIH HHS [K08 AI091663] Funding Source: Medline
Ask authors/readers for more resources
Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients. Our recent work revealed the immunological effects of blocking the CTLA4 and PD-1 immune checkpoints on T cell receptor usage among peripheral blood cells, and further uncovers how the expansion of the T cell repertoire matches the immunotoxicity profile of the therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
